Eikonoklastes Therapeutics

Eikonoklastes Therapeutics is a private, pre-clinical biotech founded in 2019 and based in Cambridge, USA, developing first-in-class gene therapies for neurodegenerative diseases. Its lead candidate, ET-101 (SynCav1), is a gene supplement therapy designed to overexpress Caveolin-1 to promote neuroprotection and synaptic function, with a planned First-in-Human trial in ALS slated for 2025. The company's strategy focuses on pursuing accelerated approvals in rare neurological disorders like ALS, where significant unmet need and compelling preclinical data create a path for rapid development and potential value creation.

First-in-class gene supplement therapy platform designed to overexpress Caveolin-1 (Cav-1) in neurons using an intraspinally delivered AAV9 vector with a neuron-specific Synapsin promoter. Aims to provide neuroprotection and enhance synaptic function to counteract neurodegenerative processes.

The ALS therapeutic landscape is active with several companies pursuing diverse approaches (antisense, small molecules, other gene therapies), but effective disease-modifying options remain extremely limited. In the broader neurodegenerative space, Eikonoklastes will compete with large pharma and biotech firms, though its specific Cav-1 mechanism is first-in-class.